Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

“DNA-based NANOdevices for the point-of-care electrochemical detection of AntiBodies”

Descrizione del progetto

Piattaforme per il rilevamento di anticorpi basate sul DNA volte ad agevolare la diagnosi

Il rilevamento degli anticorpi svolge un ruolo determinante nella diagnosi di numerose patologie, tra cui le malattie oncologiche, autoimmuni e infettive. Il progetto DNA-NANO-AB, finanziato dall’UE, propone lo sviluppo di nanodispositivi elettrochimici rapidi, intuitivi, sensibili ed economici basati sul DNA volti al rilevamento di anticorpi clinicamente rilevanti che potrebbero essere introdotti come applicazioni decentrate. Il progetto raggiungerà il suo obiettivo tramite la progettazione razionale e la produzione di piattaforme monouso di sensori basate sul DNA, in cui il rilevamento di anticorpi specifici sarà potenziato attraverso un approccio di lettura elettrochimico. Le piattaforme sviluppate saranno caratterizzate, ottimizzate e testate utilizzando livelli di immunoglobulina in campioni rappresentativi reali.

Obiettivo

WHY: Antibody detection plays a pivotal role in the diagnosis of many human disorders including infectious, autoimmune, and oncological diseases. Unfortunately, current methods routinely used for the detection of these biomarkers still require sophisticated equipment, washing intensive, reagent-intensive multi-step processes. In attempt to overcome the cited limitations, it’s mandatory find new approaches for the sensitive detection of antibodies.
WHAT: DNA-NANO-AB proposes the development of DNA-based novel, rapid, user friendly, robust, sensitive and low cost electrochemical NANOdevices for orthogonal multiplex detection of antibodies that may be advantageous over existing methods for the detection of clinically-relevant antibodies and could be well-positioned for point-of-care applications.
I will achieve this goal by rationally designing and fabricating disposable DNA-based sensing platforms in which the detection of specific antibodies will be signaled, and amplified, through an electrochemical read-out approach. The developed platforms will be characterized, optimized and then tested for the dosage of immunoglobulins levels directly in real representative samples.
HOW: During the fellowship I will undertake a training program to develop skills and acquire expertise in molecular biology, electrochemical biosensor and DNA Nanotechnology. To achieve these objectives, I will combine the different scientific backgrounds and expertise of two leading scientists: Prof. Plaxco (University of California Santa Barbara), a world-wide expert in electrochemical biosensors, and Prof. Ricci (University of Rome, Tor Vergata), a young researcher active at the forefront of DNA nanotechnology for diagnostic and drug-delivery applications. Thanks to this MSC Fellowship, I will diversify my scientific knowledge and acquire cutting-edge competences as well as complementary skills, which will become the foundation of my scientific independence.

Coordinatore

UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Contribution nette de l'UE
€ 251 002,56
Indirizzo
VIA CRACOVIA 50
00133 Roma
Italia

Mostra sulla mappa

Regione
Centro (IT) Lazio Roma
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 251 002,56

Partner (1)